# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Hatshepsut (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-AC006-SYN
- Date: 2026-07-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Amunet Okafor-Harrington, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Fourteen-week review: A1c, lipids, weight, periodontal therapy, knees, and screening results. **S**

## History of present illness

Ms. Hatshepsut returns fourteen weeks after diabetes was found. She has taken semaglutide 0.5 mg weekly for three weeks, with mild fullness after large meals and no vomiting, with metformin 1000 mg and atorvastatin 20 mg each evening. She finished scaling and root planing six weeks ago; her gums bleed less. Her screening mammogram last week was normal, and the HPV test, the fecal immunochemical test, and the HIV and hepatitis tests were negative. She walks about 120 minutes a week and climbs the stairs at the sites with less knee pain. **S**

| Element | Detail |
|---|---|
| Medicines | Semaglutide 0.5 mg weekly, metformin 1000 mg, atorvastatin 20 mg |
| Gums | Scaling and root planing completed; bleeding less |
| Screening | Mammogram normal; HPV, FIT, HIV and hepatitis tests negative |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight falling slowly |
| Gastrointestinal | Positive | Mild fullness after large meals; no vomiting or abdominal pain |
| Musculoskeletal | Positive | Knee pain on stairs, much less than before; no muscle aches on the statin |
| Psychiatric | Negative | Mood good |

4 systems reviewed. **S**

## Current medications

- Metformin extended-release 500 mg tablet, one tablet with the evening meal for one week, then two tablets (1000 mg) with the evening meal **S**
- Diclofenac sodium 1% gel, 4 g to each painful knee up to four times a day as needed **S**
- Semaglutide 0.5 mg subcutaneous injection once weekly (maintenance dose for now) **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/76 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 88.6 kg; BMI 34.6 kg/m². All vital signs are synthetic.

Hemoglobin A1c: 6.6% (high); Total cholesterol: 152 mg/dL; HDL cholesterol: 48 mg/dL (low); Triglycerides: 140 mg/dL; LDL cholesterol (calculated): 76 mg/dL; ALT: 27 U/L; PHQ-9: 2. All results are synthetic.

## Change since baseline

- Hemoglobin A1c: 7.6% (high) at baseline, 6.6% (high) at this visit **S**
- Total cholesterol: 214 mg/dL (high) at baseline, 152 mg/dL at this visit **S**
- HDL cholesterol: 44 mg/dL (low) at baseline, 48 mg/dL (low) at this visit **S**
- Triglycerides: 210 mg/dL (high) at baseline, 140 mg/dL at this visit **S**
- LDL cholesterol (calculated): 128 mg/dL at baseline, 76 mg/dL at this visit **S**
- ALT: 31 U/L at baseline, 27 U/L at this visit **S**
- PHQ-9: 4 at baseline, 2 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 88.6 kg, BMI 34.6; blood pressure 120/76, pulse 74 |
| Mouth | Gums pinker, less calculus |
| Knees | Crepitus; no effusion |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Type 2 diabetes, at goal** (E11.65). A1c 6.6%, down from 7.6%, below the goal of 7%, on metformin, semaglutide and the periodontal treatment. No hypoglycemia. **S**
   - Continue metformin 1000 mg and semaglutide 0.5 mg; stay at 0.5 mg while she is losing weight and tolerating it.
   - A1c in three months, then every six months once stable.
   - Endocrinology is not needed while she is at goal.
2. **Obesity, class 2** (E66.812). Weight 88.6 kg, down 4.4 kg (5%) since intake; she is pleased that the stairs are easier. **S**
   - Strengthening exercise and protein to protect muscle and bone.
3. **Periodontitis after therapy** (K05.323). Inflammation settling after scaling and root planing. **S**
   - Periodontal maintenance every three months with the dental team.
4. **Knee osteoarthritis** (M17.0). Less pain with exercise, weight loss and topical diclofenac. **S**
   - Continue the program; diclofenac gel as needed.
5. **Cardiovascular risk**. LDL 76 mg/dL on atorvastatin 20 mg, below 100 mg/dL; ALT normal; no muscle symptoms. **S**
   - Continue atorvastatin; lipids yearly.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin A1c | Every three months until at goal or after a change in therapy, then every six months | Completed today | 6.6%, down from 7.6% |
| Examination | Blood pressure (goal below 130/80) | Every visit | Completed today | 120/76 |
| Examination | Weight and BMI, recorded with her permission | Every visit | Completed today | 88.6 kg, BMI 34.6; down 5% since intake |
| Medication safety | Metformin: dose, tolerance and sick-day rules | Every visit | Completed today | 1000 mg tolerated |
| Medication safety | GLP-1 receptor agonist: dose, nausea, warning signs | Every visit | Completed today | 0.5 mg for three weeks; mild fullness only; no pancreatitis or gallbladder symptoms |
| Laboratory | Lipid panel and ALT on a statin | 4 to 12 weeks after starting a statin, then yearly | Completed today | LDL 76 mg/dL, HDL 48, triglycerides 140, total 152; ALT 27 U/L |
| Laboratory | Urine albumin-to-creatinine ratio and eGFR | Yearly | Up to date | Normal at intake; next in nine months |
| Examination | Comprehensive foot examination | Yearly | Up to date | Normal at the six-week visit |
| Imaging | Diabetic eye screening | Every one to two years without retinopathy | Up to date | No retinopathy at the six-week visit |
| Survey | Depression screen (PHQ-9) | At diagnosis and at least yearly | Completed today | PHQ-9 2 |
| Survey | Diabetes distress screen | At diagnosis and at least yearly | Deferred | Missed: the CMID diabetes monograph calls for a diabetes distress screen at diagnosis and yearly, and none was done at intake or since. Judging by her low PHQ-9 and GAD-7 scores and her engagement, no harm resulted. Corrective action: a two-item diabetes distress screen at the next visit, added to the diabetes visit template |
| Self-management | Diabetes self-management education and nutrition therapy | At diagnosis, then yearly | Completed today | All four sessions completed |
| Examination | Dental and periodontal care | Periodontal maintenance every three months | Completed today | Scaling and root planing completed six weeks ago; maintenance booked |
| Examination | Knee pain and function | Every visit | Completed today | Less pain on stairs |
| Medication safety | Hepatitis B vaccine, dose 2 | At least four weeks after dose 1 | Due | Dose 1 three weeks ago; dose 2 at a nurse visit next week |

## Goal progress

- Dental infection drained and the tooth removed within 24 hours, with no spread of infection. Outcome by 2026-04-15: Drained and extracted the next day; no spread. **S**
- Hemoglobin A1c below 7% within four months. Outcome by 2026-07-21: A1c 6.6% at fourteen weeks. **S**
- LDL cholesterol below 100 mg/dL on a statin. Outcome by 2026-07-21: LDL 76 mg/dL on atorvastatin. **S**
- Periodontal therapy completed and three-monthly maintenance arranged. Outcome by 2026-07-21: Scaling and root planing completed; maintenance every three months. **S**
- Climb stairs at the building sites with less knee pain, and walk 150 minutes a week. Outcome by 2026-07-21: Walking about 120 minutes a week; knee pain on stairs eased. **S**

## Guideline basis

- Standards of Care in Diabetes—2026 (Section 2, Diagnosis and Classification of Diabetes; Section 9, Pharmacologic Approaches to Glycemic Treatment) (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1):S27-S49 and S183-S215)
- Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026 (Section 8) (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1):S166-S182)
- Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (Section 10) (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1):S216-S245)
- Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology (2018), European Federation of Periodontology and International Diabetes Federation (J Clin Periodontol 2018;45(2):138-149)
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee (2019), American College of Rheumatology (Arthritis Care Res 2020;72(2):149-162)
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, rheumatoid arthritis and osteoarthritis, and hyperlipidemia monographs (2026), Aether Forge
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Review in three months with A1c; periodontal maintenance every three months; second hepatitis B dose next week; influenza and COVID-19 vaccines in the autumn; next preventive visit in one year. **S**

